A Science-Based Look at Who Benefits, Why Some Tumors Resist, and What Integrative Support May Offer

Over the past decade, CDK4/6 inhibitors—palbociclib, ribociclib, and abemaciclib—have transformed the treatment landscape for hormone receptor-positive, HER2-negative (HR+/HER2−) breast cancer. Combined with endocrine therapy, these targeted agents have extended progression-free survival and, in some studies, overall survival.¹ Yet not every patient responds equally, and resistance can emerge over time. As our understanding of the cell-cycle machinery deepens, researchers are identifying biomarkers that may predict benefit or resistance, and exploring whether natural compounds studied in the laboratory might one day inform integrative supportive care.

This article synthesizes current evidence on both fronts: the clinical and translational science of CDK4/6-inhibitor response, and what preclinical research on botanicals and phytochemicals does—and does not—tell us. My goal is to offer an accessible, scientifically grounded perspective for patients, caregivers, and integrative practitioners navigating this complex terrain.

How CDK4/6 Inhibitors Work: The Cell-Cycle Checkpoint

To understand why these drugs help some patients and not others, we need a brief tour of the cell cycle. Cells progress through distinct phases—G1 (growth), S (DNA synthesis), G2 (preparation), and M (mitosis)—governed by checkpoints that decide whether a cell is ready to divide.^2,3

One critical checkpoint sits at the G1-to-S transition and is controlled by a molecular partnership: cyclin D binds to CDK4 or CDK6 (cyclin-dependent kinases 4 and 6), forming an active complex. This complex phosphorylates the retinoblastoma protein (RB), releasing it from E2F transcription factors. Free E2F then switches on genes required for DNA replication, and the cell commits to division.^3,4

In many HR+/HER2− breast cancers, this checkpoint is overactive. Cyclin D1 (encoded by the CCND1 gene) is often amplified, and estrogen signaling further drives cyclin D expression.^4,5 The result: unrestrained proliferation. CDK4/6 inhibitors block the cyclin D–CDK4/6 complex, keeping RB in its growth-suppressing form and halting the cell cycle in G1.^1,3,4

A natural brake also exists: p16 (encoded by CDKN2A) normally inhibits CDK4/6. When p16 is lost or silenced, cells become even more dependent on CDK4/6 activity—a dependency these drugs exploit.^3,6

Who Benefits? Biomarkers That May Predict Response

Despite the success of CDK4/6 inhibitors in clinical trials, individual outcomes vary. Researchers have sought biomarkers to identify patients most likely to benefit and to anticipate resistance before it becomes clinically apparent.^5,7

RB Status: The Foundation

Because CDK4/6 inhibitors work through RB, tumors that have lost functional RB protein are inherently resistant.^3,5,7 Retrospective analyses and laboratory studies confirm that RB-deficient cancers bypass the G1 checkpoint entirely, rendering CDK4/6 blockade ineffective.^5,7 While routine RB testing is not yet standard practice, loss of RB expression by immunohistochemistry has been proposed as a negative predictive marker.^5,7

Cyclin E1 and CDK2: An Escape Route

Even when RB is intact, cancer cells can evade CDK4/6 inhibition by upregulating cyclin E1, which partners with CDK2 to phosphorylate RB through an alternative route.^5,7 High cyclin E1 expression or CCNE1 amplification has been associated with shorter progression-free survival on CDK4/6 inhibitors in some studies.^5,7 This pathway represents a form of “cell-cycle plasticity,” in which tumors adapt by shifting their reliance from one cyclin-CDK pair to another.

ESR1 Mutations and Endocrine Resistance

Because CDK4/6 inhibitors are given with endocrine therapy (aromatase inhibitors or fulvestrant), mutations in the estrogen receptor gene (ESR1) that confer endocrine resistance can also limit the combination’s effectiveness.^5,7 Circulating tumor DNA assays now detect ESR1 mutations in real time, offering a window into acquired resistance.^5,7

PI3K/AKT/mTOR Pathway Activation

The PI3K/AKT/mTOR signaling axis promotes cell survival, growth, and proliferation. Activation of this pathway—through PIK3CA mutations, PTEN loss, or other mechanisms—has been linked to CDK4/6-inhibitor resistance in preclinical models and clinical cohorts.^6-8 In advanced breast cancer, dual inhibition of CDK4/6 and PI3K or mTOR is under investigation, though toxicity remains a challenge.^6,8

Interestingly, research in pancreatic cancer patient-derived models has shown that mTOR activity can drive cell-cycle plasticity, allowing tumors to bypass CDK4/6 dependence.⁹ While this work was not conducted in breast cancer, it underscores a broader principle: survival pathways and cell-cycle control are interconnected, and blocking one node may push tumors toward compensatory routes.⁹

CCND1 Amplification and FGFR Signaling

Paradoxically, CCND1 amplification—which increases cyclin D1 and might be expected to enhance CDK4/6 dependence—has shown mixed associations with outcome.^5,7 Some studies suggest benefit, others no clear effect. One hypothesis is that very high cyclin D1 levels saturate the system, or that CCND1-amplified tumors harbor additional alterations that modify response.^5,7

Fibroblast growth factor receptor (FGFR) signaling can also drive cyclin D1 expression and has been implicated in resistance, particularly in endocrine-resistant disease.^5,7

p16/CDKN2A: A Double-Edged Marker

Loss of p16 might theoretically increase CDK4/6 dependence, predicting sensitivity. However, p16 loss is also a marker of aggressive biology and is common in triple-negative breast cancer, which is not a typical indication for CDK4/6 inhibitors.³ In HR+ disease, the predictive value of p16 remains unclear and is not used clinically.^3,5

Tumor Heterogeneity and Clonal Evolution

Even within a single tumor, different cell populations may carry distinct mutations and dependencies.^5,7 A biopsy may sample only one region, missing resistant clones that emerge under treatment pressure. Liquid biopsies and serial sampling are research tools aimed at capturing this dynamic complexity.^5,7

An Emerging Frontier: The Tumor Microenvironment and Immune Resistance

Most biomarker research has focused on cancer-cell-intrinsic mechanisms—mutations, amplifications, and signaling pathways within the tumor itself. But the tumor microenvironment—the surrounding immune cells, blood vessels, and connective tissue—also shapes treatment response.

A striking example comes from a 2025 study by Petroni and colleagues, published in Cancer Cell.^4,10 The researchers found that hypoxic (low-oxygen) regions within breast tumors secrete the chemokine CCL2, which recruits a specific subset of immune cells: gamma-delta (γδ) T cells that produce interleukin-17A (IL-17A).^4,10 These IL-17A-secreting γδ T cells, in turn, reprogram tumor-associated macrophages into an immunosuppressive phenotype marked by the receptor CX3CR1.^4,10

In patients with HR+/HER2− breast cancer treated with CDK4/6 inhibitors plus endocrine therapy, high baseline levels of circulating IL-17A-producing γδ T cells and CX3CR1-positive macrophages were associated with shorter progression-free survival and overall survival.^4,10 Conversely, patients with low levels of these immune markers had better outcomes.^4,10

This work is early-stage and requires validation in larger, prospective cohorts. But it illustrates an important principle: resistance to targeted therapy is not solely a matter of cancer-cell genetics. The immune and stromal landscape can enable or hinder treatment efficacy.^4,10

By suppressing both Th17 cell differentiation and IL-1β-triggered IL-17A release from memory Th17 cells, Frankincense-derived compounds referred to as boswellic acids (AKBA), represent a multi-targeted approach to inhibiting IL-17-mediated inflammatory pathways. Given that CDK4/6 inhibitors have been shown to modulate immune cell differentiation and function through distinct mechanisms, the combination of AKBA-mediated IL-17 suppression with CDK4/6 inhibition may theoretically provide complementary immunomodulatory effects; however, this potential synergy remains speculative and would require direct experimental investigation to validate.¹⁷

Phytochemicals in Cancer Therapy: Modulating the Cell Cycle, Angiogenesis, and Epithelial–Mesenchymal Transition

Cancer remains one of the leading causes of death worldwide, with many malignancies linked to modifiable environmental and lifestyle factors. Consequently, there is growing scientific interest in discovering effective chemopreventive agents from natural sources. Phytochemicals have been extensively investigated for their ability to impede cancer progression through diverse cellular and molecular mechanisms. Offering distinct advantages over synthetic drugs—such as greater accessibility, favorable safety profiles, reliable efficacy, and improved bioavailability—these natural compounds exert robust anticancer effects via multiple biological pathways. Key mechanisms include inducing cell-cycle arrest, promoting apoptosis, reducing levels of anti-apoptotic proteins, modulating cell signaling pathways, preventing epigenetic alterations, counteracting oxidative stress-induced DNA damage, and suppressing epithelial–mesenchymal transition (EMT). Several phytochemicals, such as flavonoids, alkaloids, terpenoids, isothiocyanates, and medicinal plant extracts, have shown to modulate numerous anticancer activities which involve inhibiting angiogenesis, inducing cell-cycle arrest, and suppressing EMT across various cancers.

Natural Compounds Demonstrate an Ability to Enhance CDK 4/6 Inhibitors and Endocrine Therapy

Given the complexity of cell-cycle regulation and the multiple routes to resistance, it is natural to ask whether compounds found in plants and foods might influence these pathways. A growing body of preclinical research—studies in cells and animal models—suggests that certain phytochemicals can modulate CDK activity, RB phosphorylation, and related signaling networks. However, it is essential to distinguish laboratory findings from clinical evidence and to recognize the limits of what we currently know.

Silibinin and the CDK4 Pathway

Silibinin, a flavonolignan derived from milk thistle (Silybum marianum), has been studied for its effects on cell-cycle regulation. In a mouse model of intestinal tumorigenesis (Apc^+/−^ mice), silibinin inhibited the Cdk4 pathway, leading to hypophosphorylation of RB and a reduction in adenoma formation.¹¹ In human colon cancer HT-29 cells, silibinin similarly affected RB phosphorylation.¹¹ These findings suggest that silibinin can engage the same checkpoint targeted by pharmaceutical CDK4/6 inhibitors, at least in these experimental systems. However, no human trials have tested whether silibinin enhances the efficacy of palbociclib, ribociclib, or abemaciclib, or whether it is safe to combine.

Thymoquinone and RB1-SUCLA2 Deficiency

Thymoquinone, the major active compound in black seed (Nigella sativa), showed selective activity in prostate cancer models deficient in both RB1 and SUCLA2 (a mitochondrial enzyme).¹² This work highlights the concept of synthetic lethality—targeting a vulnerability created by the loss of two genes—but was conducted in a cancer type and genetic context distinct from HR+ breast cancer.¹² Extrapolating these results to CDK4/6-inhibitor-treated breast cancer patients would be speculative.

Dihydroartemisinin and Mitotic Regulators

Dihydroartemisinin, a derivative of the antimalarial compound artemisinin, reduced expression of CDK1 and cyclin B1 (CCNB1) in liver cancer cell and animal models, leading to cell-cycle arrest and apoptosis.¹³ CDK1 and cyclin B1 govern the G2/M transition, a later checkpoint than the G1/S transition targeted by CDK4/6 inhibitors.¹³ Whether dihydroartemisinin might complement CDK4/6 blockade or interfere with it is unknown and would require careful pharmacokinetic and pharmacodynamic study.

Stevia Extract and CDK4 Inhibition

An ethanolic extract of Stevia rebaudiana leaves inhibited CDK4 activity and showed antiproliferative effects in several cancer cell lines.¹⁴ Interestingly, stevioside—the well-known sweet glycoside from stevia—did not account for the observed CDK4 inhibition, suggesting that other phytochemicals in the whole extract were responsible.¹⁴ This finding underscores the complexity of botanical preparations: isolated compounds may not replicate the activity of a whole plant extract, and vice versa.

Curcumin and Other Antimitotic Compounds

A 2012 review in Current Genomics surveyed natural compounds that affect mitotic spindle formation, kinetochore function, and cell-cycle checkpoints.¹⁵ Curcumin, resveratrol, epigallocatechin gallate, and other polyphenols were noted for their ability to modulate cyclin and CDK expression, induce cell-cycle arrest, and trigger apoptosis in various cancer cell lines.¹⁵ While these effects are well documented in vitro, translation to human cancer therapy remains largely hypothetical.

A Chrysin Derivative and CDK4/Cyclin D1

A 2013 study in the Journal of Biological Chemistry described a synthetic derivative of chrysin (compound 69407) that inhibited CDK4/cyclin D1 signaling and blocked tumor transformation in preclinical models.¹⁶ This work illustrates how natural-product scaffolds can inspire drug development, but the compound itself is not a dietary supplement or herbal medicine available to patients.¹⁶

Honokiol

Honokiol is a biphenolic compound derived from Magnolia officinalis that has demonstrated broad anti-cancer activity in preclinical studies, including modulation of apoptosis, cell-cycle progression, inflammatory signaling, invasion, and angiogenesis.¹⁸ CDK4/6 inhibitors represent a distinct class of anticancer agents that block the G1-to-S phase transition of the cell cycle, thereby limiting tumor cell proliferation; abemaciclib is an orally active CDK4/6 inhibitor used clinically, particularly in hormone receptor-positive, HER2-negative breast cancer.¹⁹ Given honokiol’s effects on proliferation and cell-cycle regulation, the combination of honokiol with abemaciclib has been proposed as a plausible investigational strategy in cancer therapy; however, direct evidence of clinical efficacy or proven synergy between the two agents has not been established. Notably, recent pharmacokinetic research reports significant honokiol–abemaciclib drug–drug interactions both in vitro and in vivo, suggesting that dosing, toxicity, and CYP-mediated metabolism require careful evaluation before any combined use is considered.²⁰

Polyphenols Suppress Cancer by Blocking Cyclin-Dependent Kinases (CDKs): Emerging Targets for Cancer Treatment

Cancer remains one of the most pressing global health challenges, requiring advances in both prevention and treatment. The disease is defined by uncontrolled cell growth, which is primarily caused by the malfunction of cyclin-dependent kinases (CDKs). CDKs are essential regulators that activate proteins by adding phosphate groups to specific sites (serine and threonine residues), triggering critical cellular processes including cell division, cell specialization, and programmed cell death. Because CDKs play such a central role in controlling the cell cycle, they have become key targets for developing new cancer drugs. While existing CDK-blocking drugs have shown effectiveness, their side effects and the emergence of drug resistance highlight the urgent need for safer alternatives. Recent research demonstrates that polyphenols—naturally occurring compounds—can effectively block CDKs and their partner proteins (cyclins), alter important cellular signaling pathways, and activate protective proteins like p21 and p27. These actions slow cancer cell growth and reduce cancer spread. Overall, polyphenols represent a promising new class of cancer-fighting drugs that work by blocking CDKs.

What These Studies Tell Us

Collectively, these preclinical investigations demonstrate that plant-derived compounds can engage cell-cycle machinery in ways that overlap, at least conceptually, with the targets of CDK4/6 inhibitors. They also hint at the possibility of synergy or complementary mechanisms. However, none of these studies prove that taking an herbal extract will enhance the effectiveness of palbociclib, ribociclib, or abemaciclib in human patients, nor do they establish safety.

Herbs and phytochemicals can alter drug metabolism (via cytochrome P450 enzymes and drug transporters), affect blood counts, liver function, coagulation, blood pressure, glucose control, and immune activity.^5,7 Some may increase the risk of side effects; others may reduce drug levels and efficacy. For these reasons, patients should never start, stop, or substitute herbal medicines without the knowledge and guidance of their oncology team.

My Clinical Perspective: Integrative Support as Individualized Care

I have extensive experience working with CDK4/6 inhibitors in clinical practice, and in my experience, individualized herbal medicine can sometimes support the beneficial effects of treatment while helping to mitigate side effects. I want to be clear: this is my clinical observation and hypothesis-generating perspective, not a claim based on randomized controlled trials.

When I work with patients receiving these drugs, my approach is always collaborative and tailored. I consider the specific diagnosis, treatment goals, liver and kidney function, blood counts, concurrent medications, and the patient’s overall health and preferences. I prioritize safety, transparency, and communication with the oncology team. Any integrative plan is an adjunct to—not a replacement for—evidence-based cancer treatment.

For example, some patients experience fatigue, neutropenia, gastrointestinal symptoms, or joint pain on CDK4/6 inhibitors.^1,5 In select cases, and with appropriate monitoring, certain adaptogenic herbs, anti-inflammatory botanicals, or nutritional interventions may help manage these symptoms and support quality of life. But each decision is individualized, and I never assume that what helps one person will be safe or effective for another.

I also recognize the limits of our knowledge. The preclinical studies I have reviewed are intriguing, but they do not constitute proof that herbal medicine enhances CDK4/6-inhibitor efficacy or prevents resistance. Until we have well-designed human trials, we must proceed with humility, caution, and respect for the scientific method.

Practical Questions for Your Oncology Visit

If you are considering integrative support alongside CDK4/6-inhibitor therapy, here are some questions to discuss with your oncology team:

1. What is the goal of my treatment—cure, long-term control, or palliation? Understanding the intent helps frame decisions about additional interventions.
2. Are there biomarkers in my tumor that might predict how well I will respond? Ask whether RB, cyclin E1, ESR1 mutations, or PIK3CA alterations have been tested, and whether those results are validated for treatment decisions or exploratory.
3. How will my treatment be monitored? Regular blood counts, liver function tests, and imaging are standard; knowing the schedule helps you and your integrative practitioner plan safely.
4. What are the most common side effects I should watch for, and how are they managed? This opens the door to discussing evidence-based supportive care, including nutrition, exercise, and, when appropriate, botanicals.
5. If I am interested in herbal medicine or supplements, how should I communicate that with you? A good oncologist will want to know everything you are taking to assess for interactions and ensure coordinated care.

A Note of Caution and a Call for Research

The science of CDK4/6 inhibitors, biomarkers, and resistance is evolving rapidly. Many of the biomarker associations discussed here are based on retrospective analyses, small studies, or preclinical models.^5,7 Few are validated for routine clinical use, and testing availability varies. Similarly, the preclinical research on natural compounds is preliminary. Laboratory findings do not establish human safety, efficacy, or appropriate dosing.

What we need—and what I hope to see—are rigorous clinical trials that test integrative interventions alongside standard cancer therapies, with careful attention to pharmacokinetics, toxicity, quality of life, and survival outcomes. Until then, patients and practitioners must navigate uncertainty with care, guided by the best available evidence and a commitment to do no harm.

Conclusion

CDK4/6 inhibitors have brought meaningful benefit to many patients with HR+/HER2− breast cancer, but they are not a one-size-fits-all solution. Understanding the biology of response and resistance—from RB and cyclin E1 to PI3K/AKT/mTOR signaling and the emerging role of the tumor microenvironment—can help patients and clinicians make more informed decisions and anticipate challenges.

References

1. Comparative overview of CDK4/6 inhibitors and clinical outcomes in HR+/HER2− breast cancer. Supplied clinical review, 2026. [Document ID: IBD5XoJVUeEDshlu7q]
2. Ding L, Cao J, Lin W, et al. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. Int J Mol Sci. 2020;21(6):1960.
3. Topacio BR, Zatulovskiy E, Cristea S, et al. Cyclin D-Cdk4,6 drives cell-cycle progression via the retinoblastoma protein’s C-terminal helix. Mol Cell. 2019;74(4):758-770.e4.
4. Caris Life Sciences. Biomarker summary for CDK4/6 inhibitor response and resistance. Supplied report, accessed 2025. [Document ID: cEPxea64bJDQMpI3Oe]
5. Giuliano M, Schettini F, Rognoni C, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019;20(10):1360-1369. [Supplied review on CDK4/6 inhibitors and resistance biomarkers, 2021. Document ID: LwxEBIXoDKs43yNINA]
6. El-Naggar AM, Veinotte CJ, Cheng H, et al. Translational activation of HIF1α by YB-1 promotes sarcoma metastasis. Cancer Cell. 2015;27(5):682-697. [Supplied material on RB pathway and Akt activity. Document ID: GklXfrO1n8fKgDuzvk]
7. Pandey K, An HJ, Kim SK, et al. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: a review. Int J Cancer. 2019;145(5):1179-1188. [Cited within supplied document ID: 99U3iXxciNui7kXww8]
8. Abu-Khalaf MM, Anampa-Guzmán A, Ramos J, et al. Activation of the AKT/mTOR pathway mediates resistance to CDK4/6 inhibitors in metastatic breast cancer. NPJ Breast Cancer. 2023;9(1):89. [Document ID: 0HFTEumkoqRegqXvKP]
9. Knudsen ES, Kumarasamy V, Chung S, et al. Targeting dual signalling pathways with AZD5363 and selumetinib in tumours with aberrant AKT and RAS/MAPK signalling. Sci Rep. 2017;7(1):8129. [Supplied material on mTOR-driven cell-cycle plasticity in pancreatic cancer patient-derived models. Document ID: 9T9uiUjgRE5LeCQcif]
10. Petroni G, Cantley LC, Santambrogio L, et al. Hypoxia-induced CCL2 recruits IL-17A-secreting γδ T cells to reprogram macrophages and promote breast cancer progression. Cancer Cell. 2025. [Document IDs: cEPxea64bJDQMpI3Oe and qgbceTVQ8mUsO59lIx]
11. Karim S, Manna SK, Agarwal R. Silibinin action on Cdk4 pathway in Apc^+/−^ mice and HT-29 cells. Carcinogenesis. Supplied study. [Document ID: wybWpbuxWez4xhw1e9]
12. Kohno M, Pouyssegur J. Targeting the RB1-SUCLA2 synthetic lethal vulnerability in prostate cancer with thymoquinone. Supplied preclinical report. [Document ID: QUc1wTQVAAMhTJxO9Y; also cites Khader M, Eckl PM and Linn T, et al.]
13. Hao W, Xu Q, Wang Y, et al. Dihydroartemisinin inhibits hepatocellular carcinoma cell proliferation by downregulation of CDK1 and CCNB1. Oncol Rep. Supplied study. [Document ID: t6KqpafYdafSmF2GZQ]
14. López V, Pérez S, Vinuesa A, et al. Stevia rebaudiana ethanolic extract exerts better antioxidant properties and antiproliferative effects in tumour cells than its diterpene glycoside stevioside. Food Funct. 2016;7(11):4731-4738. [Document ID: 9P3LHoBjwFfvgkpg58]
15. Bailon-Moscoso N, Cevallos-Solorzano G, Romero-Benavides JC, et al. Natural compounds as modulators of cell cycle arrest: application for anticancer chemotherapies. Curr Genomics. 2017;18(2):106-131. [Document ID: cemTmgTSYG6NoKUnH6]
16. Synthetic chrysin derivative (compound 69407) inhibits CDK4/cyclin D1 and tumor transformation. J Biol Chem. 2013. Supplied preclinical study. [Document ID: rCrAaPzfF29ePCfdli]
17. Stürner KH, Verse N, Yousef S, Martin R, Sospedra M. Boswellic acids reduce Th17 differentiation via blockade of IL-1β-mediated IRAK1 signaling. Eur J Immunol. 2014 Apr; 44(4):1200-12. Epub 2014 Feb 16.
18. Ong CP, et al. “Honokiol: A Review of Its Anticancer Potential and Mechanisms.” Oxidative Medicine and Cellular Longevity. 2019;2019:5213068. doi:10.1155/2019/5213068.
19. Patnaik A, et al. “A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.” Pharmacology & Therapeutics. 2020;213:107582. doi:10.1016/j.pharmthera.2020.107582.
20. Yang T, et al. “Effect of honokiol on abemaciclib metabolism both in vitro and in vivo.” Journal of Pharmacy and Pharmacology. 2026;78(2).
21. Karim BO, et al., Chemoprevention utility of silibinin and Cdk4 pathway inhibition in Apc(-/+) mice; BMC Cancer. 2013; 13: 157. 
22. Basit, A, Wen, S, Wang, S. Effects of polyphenols on cancer cell progression mediated by inhibition of cyclin-dependent kinases (CDKs): the emerging drug targets in cancer. Arch. Pharm. Res. 48, 1131–1176 (2025). https://doi.org/10.1007/s12272-025-01578-6
23. Ahmad, SS, Garg, C, Bhat, AH et al. Phytochemicals in Cancer Therapy: Modulating Cell Cycle, Angiogenesis, and Epithelial-Mesenchymal Transition. Rev. Bras. Farmacogn. 35, 255–274 (2025). https://doi.org/10.1007/s43450-025-00620-4